$IMMX
Immix Biopharma, Inc.
A volume-weighted average price line from the last reported earnings date through today.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- CEO
- Dr. Ilya Rachman M.B.A., M.D., Ph.D.
- Employees
- 21
- Headquarters
- Los Angeles, CA
- Sector
- Healthcare
- Industry
- Biotechnology
- Website
- immixbio.com
Key stats
- Market Cap
- $998.79M
- P/E Ratio
- —
- Avg Volume (3M)
- 1.83M
- EPS
- -$0.88
- Day's Range
- $13.52 – $14.15
Fundamentals as of Sep 01, 2026